|Print Page Close Window|
MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.Read More
Recent Press Releases
11/15/17Preclinical Studies with MyoKardia’s Mavacamten Demonstrate Evidence of Reduced Contractility and Improved Left Ventricular Compliance
11/13/17MyoKardia Presents Data from Study of Machine Learning Algorithm Intended to Identify Obstructive Hypertrophic Cardiomyopathy Using a Wearable Biosensor
NASDAQ GS | MYOK (Common Stock)
$36.85 - 0.35
11/20/174:00 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.
There are currently no events scheduled.